27th Sep 2006 14:31
27 September 2006Shire plc (the "Company")The Company announces that it was notified on 26 September 2006 under Sections198 to 202 of the Companies Act that FMR Corp. and its direct and indirectsubsidiaries and Fidelity International Limited and its direct and indirectsubsidiaries, both being non-beneficial holders, held solely for investmentpurposes, in aggregate 20,830,990 ordinary shares of ‚£0.05p each in the capitalof the Company. These holdings represent 4.15 per cent of the issued ordinaryshare capital of the Company.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 5492592Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire